Corporate press releases announcing information that is material to investors, and clinical investigator comments about pipeline drugs, can create pre-approval promotion enforcement risks for biopharma companies, regulatory and legal experts say.
When it comes to corporate communications, companies should begin with information that needs to be disclosed to satisfy Securities and...